311 related articles for article (PubMed ID: 9436961)
1. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis.
Coffin CM; Rulon J; Smith L; Bruggers C; White FV
Mod Pathol; 1997 Dec; 10(12):1175-87. PubMed ID: 9436961
[TBL] [Abstract][Full Text] [Related]
2. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS).
Smith LM; Anderson JR; Coffin CM
Med Pediatr Oncol; 2002 Jun; 38(6):398-404. PubMed ID: 11984800
[TBL] [Abstract][Full Text] [Related]
3. The expression pattern of contractile and intermediate filament proteins in developing skeletal muscle and rhabdomyosarcoma of childhood: diagnostic and prognostic utility.
Wijnaendts LC; van der Linden JC; van Unnik AJ; Delemarre JF; Voute PA; Meijer CJ
J Pathol; 1994 Dec; 174(4):283-92. PubMed ID: 7884590
[TBL] [Abstract][Full Text] [Related]
4. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
5. A new marker for rhabdomyosarcoma. Insulin-like growth factor II.
Yun K
Lab Invest; 1992 Nov; 67(5):653-64. PubMed ID: 1434543
[TBL] [Abstract][Full Text] [Related]
6. Myoglobin, desmin and vimentin in ultrastructurally proven rhabdomyomas and rhabdomyosarcomas. An immunohistochemical study utilizing a series of monoclonal and polyclonal antibodies.
Seidal T; Kindblom LG; Angervall L
Appl Pathol; 1987; 5(4):201-19. PubMed ID: 3689591
[TBL] [Abstract][Full Text] [Related]
7. Therapy associated differentiation in rhabdomyosarcomas.
d'Amore ES; Tollot M; Stracca-Pansa V; Menegon A; Meli S; Carli M; Ninfo V
Mod Pathol; 1994 Jan; 7(1):69-75. PubMed ID: 8159655
[TBL] [Abstract][Full Text] [Related]
8. Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma.
Paner GP; McKenney JK; Epstein JI; Amin MB
Am J Surg Pathol; 2008 Jul; 32(7):1022-8. PubMed ID: 18469707
[TBL] [Abstract][Full Text] [Related]
9. Myogenin and desmin immunohistochemistry in the assessment of post-chemotherapy genitourinary embryonal rhabdomyosarcoma: prognostic and management implications.
Godbole P; Outram A; Wilcox DT; Duffy PG; Sebire NJ
J Urol; 2006 Oct; 176(4 Pt 2):1751-4. PubMed ID: 16945640
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors.
Granzen B; Efferth T; Keller U; Beniers AJ; Mertens R; Jakse G; Füzesi L
Anticancer Res; 2001; 21(1B):771-6. PubMed ID: 11299842
[TBL] [Abstract][Full Text] [Related]
11. Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma.
Oda Y; Kohashi K; Yamamoto H; Tamiya S; Kohno K; Kuwano M; Iwamoto Y; Tajiri T; Taguchi T; Tsuneyoshi M
Cancer Sci; 2008 Apr; 99(4):726-32. PubMed ID: 18377424
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas.
Iino K; Sasano H; Yabuki N; Oki Y; Kikuchi A; Yoshimi T; Nagura H
Mod Pathol; 1997 Sep; 10(9):901-7. PubMed ID: 9310953
[TBL] [Abstract][Full Text] [Related]
14. Intermediate filament proteins and actin isoforms as markers for soft tissue tumor differentiation and origin. II. Rhabdomyosarcomas.
Skalli O; Gabbiani G; Babaï F; Seemayer TA; Pizzolato G; Schürch W
Am J Pathol; 1988 Mar; 130(3):515-31. PubMed ID: 3279794
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
[TBL] [Abstract][Full Text] [Related]
16. Chemically induced rhabdomyosarcomas in rats. Ultrastructural, immunohistochemical, biochemical features and expression of alpha-actin isoforms.
Babai F; Skalli O; Schurch W; Seemayer TA; Gabbiani G
Virchows Arch B Cell Pathol Incl Mol Pathol; 1988; 55(5):263-77. PubMed ID: 2901166
[TBL] [Abstract][Full Text] [Related]
17. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues.
Kumar S; Perlman E; Harris CA; Raffeld M; Tsokos M
Mod Pathol; 2000 Sep; 13(9):988-93. PubMed ID: 11007039
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic sarcoma of the kidney: a clinicopathologic study of 20 cases of a new entity with polyphenotypic features.
Vujanić GM; Kelsey A; Perlman EJ; Sandstedt B; Beckwith JB
Am J Surg Pathol; 2007 Oct; 31(10):1459-68. PubMed ID: 17895746
[TBL] [Abstract][Full Text] [Related]
19. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
20. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
